A5032979634- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Antiplatelet Therapy and Cardiovascular Diseases
- Cancer-related gene regulation
- Blood groups and transfusion
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Blood properties and coagulation
- Heparin-Induced Thrombocytopenia and Thrombosis
- Venous Thromboembolism Diagnosis and Management
- Uterine Myomas and Treatments
- Pregnancy and preeclampsia studies
- Blood disorders and treatments
- Cardiovascular Issues in Pregnancy
- Hemoglobinopathies and Related Disorders
- Prenatal Screening and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Gynecological conditions and treatments
- Ectopic Pregnancy Diagnosis and Management
- Endometriosis Research and Treatment
- Atrial Fibrillation Management and Outcomes
- HIV-related health complications and treatments
- Blood donation and transfusion practices
Centers for Disease Control and Prevention
2013-2022
National Center on Birth Defects and Developmental Disabilities
2012-2022
Synergy America (United States)
2020-2022
Eunice Kennedy Shriver National Institute of Child Health and Human Development
2006
Weatherford College
2006
National Institutes of Health
2005
United States Department of Health and Human Services
2002-2003
National Center for Infectious Diseases
2001-2002
Emory University
2001
Northwestern University
1996-1998
In Brief Objective: We sought to estimate the frequency of pregnancy-related thromboembolic events among carriers factor V Leiden (FVL) mutation without a personal history thromboembolism, and evaluate impact maternal fetal FVL carriage or other thrombophilias on risk adverse outcomes. Methods: Women with singleton pregnancy no thromboembolism were recruited at 13 clinical centers before 14 weeks gestation from April 2000 August 2001. Each was tested for mutation, as resultant conceptus...
The previously published mortality studies are limited in hemophilia populations but suggest that there is no increased risk of factor VIII inhibitor patients. This retrospective study analyzed surveillance data collected on 7,386 males with severe A over a 13-year period to assess the association between current and death. During period, 432 participants died, among whom 48 were patients an inhibitor. Clinical characteristics most strongly associated death number reported bleeds, signs...
The optimal management of menorrhagia among women with abnormal laboratory haemostasis is uncertain. In a crossover study, 116 [pictorial blood assessment chart (PBAC) score >100], negative gynaecological evaluation and were randomly assigned to either intranasal desmopressin (IN-DDAVP) or tranexamic acid (TA) therapy for two menstrual cycles. subjects then crossed over the second study drug additional Menstrual loss (MBL) was measured by PBAC scores at baseline after each cycle. Quality...
Summary. Both genetic and treatment‐related risk factors contribute to the development of inhibitors in haemophilia. An inhibitor surveillance system piloted at 12 US sites has goal assessing through prospective data collection. This report examines relationship genotype race/ethnicity history a large cohort haemophilia patients. Mutation analysis was performed on 676 A (HA) 153 B (HB) patients by sequencing, Multiplex Ligation‐dependent Probe Amplification, PCR for inversions F8 introns 22...
In Brief OBJECTIVE: A study was conducted to evaluate the frequency and types of hemostatic defects occurring in adolescent perimenopausal-age women diagnosed with menorrhagia. METHODS: total 115 a physician diagnosis menorrhagia, including 25 women, 65 between ages 20 44, underwent comprehensive testing for possible bleeding disorders. Frequencies disorders were calculated compared. RESULTS: Forty-seven percent found have abnormalities, platelet dysfunction, von Willebrand's disease,...
Estimates of the size and characteristics US haemophilia population are needed for healthcare planning resource needs assessment. A network comprehensive treatment centres (HTCs) located throughout United States receives federal support diagnosis management other rare bleeding disorders.Estimate incidence prevalence among males using HTC network.During period 2012-2018, de-identified surveillance data were collected on all who visited an that included year birth, gender, race, Hispanic...
Hemophilia B (HB) is caused by mutations in the human gene F9. The mutation type plays a pivotal role genetic counseling and prediction of inhibitor development. To help HB community understand molecular etiology HB, we have developed listing all F9 that are reported to cause based on literature existing databases. Centers for Disease Control Prevention (CDC) Mutation Project (CHBMP) list compiled an easily accessible format Microsoft Excel contains 1083 unique HB. Each identified using...
Abstract Diagnosis of von Willebrand disease (vWD) is based on a panel laboratory tests that measure the amount and function factor (vWF). In population studies, vWF higher in African Americans than Caucasians. Bleeding time, VIII activity (FVIII), antigen (vWF:Ag), “vWF activity” ELISA (vWF:Act), ristocetin cofactor (vWF:RCof), ristocetin‐induced platelet aggregation (RIPA) were measured 123 women with menorrhagia randomly selected control women; 70 cases 76 controls American. Among...
Genotyping efforts in hemophilia A (HA) populations many countries have identified large numbers of unique mutations the Factor VIII gene (F8). To assist HA researchers conducting genotyping analyses, we developed a listing F8 including those listed existing locus-specific databases as well patient and reported literature. Each mutation was reviewed uniquely using Human Genome Variation Society (HGVS) nomenclature standards for coding DNA predicted protein changes traditional based on...
Little is known about rates of joint bleeding among females with FVIII/FIX deficiency or hemophilia carriers. In a cross-sectional study, we tested the hypothesis that FVIII FIX enrolled in Universal Data Collection (UDC) project had reduced mean overall range motion (ROM) compared historic controls from Normal Joint Study. Demographics, clinical characteristics, and ROM measurements on 303 without disorder 148 deficiency, respectively, between ages 2-69 years body mass index (BMI) ≤ 35 were...
Summary To assess sources of variability in platelet function tests normal subjects, 64 healthy young adults were tested on 2–6 occasions at 2 week intervals using four methods: aggregation ( AGG ) platelet‐rich plasma PRP the Bio/Data PAP ‐4 Aggregometer BD and C hrono‐ L og umi‐ A ggregometer CL ); whole blood WB M ultiplate P latelet F unction nalyser MP ), with ATP release REL ‐ . Food medication exposures recorded prospectively for weeks prior to each draw. At least one abnormality was...
Abstract Introduction Females may have haemophilia with the same factor VIII (FVIII) or IX (FIX) levels as affected males. Characterization of females would be useful for health care planning to meet their unique needs. Federally‐funded treatment centres (HTCs) in United States contribute data on all individuals bleeding disorders receiving Population Profile (HTC PP) component Community Counts Public Health Surveillance Bleeding Disorders project. Aims To estimate number at HTCs and compare...
Summary. While an estimated 13% of women with unexplained menorrhagia have von Willebrand disease (VWD), the frequency other potential bleeding disorders has been uncertain. This study describes relatively wide range laboratory characteristics and presents issues affecting diagnosis in this population. Women pictorial blood assessment chart (PBAC) score >100 were identified at six U.S. sites asked to remain drug free for 10 days prior testing. Blood was collected on one first four...
Summary Inhibitors are a rare but serious complication of treatment patients with haemophilia. Phase III clinical trials enrol too few to adequately assess new product inhibitor risk. This project explores the feasibility using public health surveillance system conduct national for inhibitors. Staff at 17 U.S. haemophilia centres ( HTC ) enrolled A and B into this prospective study. staff provided detailed historic data on use inhibitors baseline, postenrolment monthly infusion logs. central...